2025 Industry Supported Session

Lunch 'n Learn 5: THE CHANGING LANDSCAPE In the Treatment of Alzheimer's Disease

Tuesday, June 10, 2025 - 12:15 PM – 1:45 PM Eastern
Rogers Centre Ottawa, Level 2, Room 208
Faculty: Andrew Frank • Sara Mitchell • Paolo Vitali

Description:
The Symposium on Advancements in Alzheimer's Research offers an in-depth exploration of the latest breakthroughs in the understanding, diagnosis, and treatment of Alzheimer's disease. This comprehensive program is designed for clinicians, and healthcare professionals, who are dedicated to combating this debilitating neurological disorder.

Learning Objectives:
- Articulate the latest scientific and clinical updates on Alzheimer's disease
- Discuss diagnostic tools and imaging techniques in the identification and treatment of Alzheimers disease
- Examine the safety and efficacy of new therpaeutic strategies and their efficacy
- Promote a discussion of collaboration among professionals in the field

Audience: Adult Neurologist, Neuroradiologist, Resident, Fellow, Nurses with interest in topic
Learning Level: Intermediate (Practicing Physician)
Learning Format: Audience response system, Discussion group/peer exchange/user groups, Forum/panels, Lecture/plenary method
CanMEDS: Medical Expert, Communicator, Collaborator, Health Advocate

Time	Presentation Title	Name of Speaker
12:15 PM ET	Welcome & Introductions	Sara Mitchell
12:20 PM ET	The State of AD in Canada	Sara Mitchell
12:25 PM ET	Diagnosis and Biomarkers	Paolo Vitali
12:40 PM ET	Q&A	Sara Mitchell, Andrew Frank, Paolo Vitali
12:45 PM ET	DMTs - Trial Design and Efficacy	Andrew Frank
1:00 PM ET	Safety and ARIAs	Paolo Vitali
1:15 PM ET	Q&A	Sara Mitchell, Andrew Frank, Paolo Vitali
1:20 PM ET	Canadian Readiness for DMTs	Sara Mitchell
1:35 PM ET	Q&A	Sara Mitchell, Andrew Frank, Paolo Vitali
1:40 PM ET	Conclusion	Sara Mitchell

This program was developed by the CNSF and Eli Lilly Canada Inc. and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.